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Abstract
Background: Post-translational modifications and genetic variations give rise to protein variants that significantly
increase the complexity of the human proteome. Modified proteins also play an important role in biological
processes. While sandwich immunoassays are routinely used to determine protein concentrations, they are
oblivious to protein variants that may serve as biomarkers with better sensitivity and specificity than their wild-type
proteins. Mass spectrometry, coupled to immunoaffinity separations, can provide an efficient mean for
simultaneous detection and quantification of protein variants.
Results: Presented here is a mass spectrometric immunoassay method for targeted quantitative proteomics
analysis of protein modifications. Cystatin C, a cysteine proteinase inhibitor and a potential marker for several
pathological processes, was used as a target analyte. An internal reference standard was incorporated into the
assay, serving as a normalization point for cystatin C quantification. The precision, linearity, and recovery
characteristics of the assay were established. The new assay was also benchmarked against existing cystatin C
ELISA. In application, the assay was utilized to determine the individual concentration of several cystatin C variants
across a cohort of samples, demonstrating the ability to fully quantify individual forms of post-translationally
modified proteins.
Conclusions: The mass spectrometric immunoassays can find use in quantifying specific protein modifications,
either as a part of a specific protein biomarker discovery/rediscovery effort to delineate the role of these variants in
the onset of the disease, progression, and response to therapy, or in a more systematic study to delineate and
understand human protein diversity.
Background
Protein modifications play important roles in biological
process, and can serve as diagnostic indicators of patho-
logical events [1]. However, their detection and quantifi-
cation is not straightforward because oftentimes these
modified forms are only slightly chemically different
from their wild-type proteins. Powerful separation meth-
ods are thus needed to differentiate protein variants in
preparation for subsequent detection. Alternatively,
mass spectrometry can detect all protein variants in a
single analysis; a MALDI mass spectrum can contain
signals from multiple protein variants, as long as the
variants (along with the targeted native protein) are not
hindered by other overabundant proteins which can
dynamically suppress their signals. In that case, some
sort of fractionation is still needed, especially when
analyzing complex samples such as human plasma and
serum. Immunoaffinity separation offers simple and tar-
geted isolation of proteins and their variants in prepara-
tion for MS detection, by using antibodies toward
invariable epitopes in the protein sequence. The result
of one such combination of immunoaffinity separation
and mass spectrometric detection is the Mass Spectro-
metric Immunoassay [2,3], which can offer something
that conventional enzymatic immunoassay cannot -
detection and quantification of protein variants. The
secondary antibody used in sandwich immunoassays
cannot discriminate between structural protein modifi-
cations and the resulting quantitative signal is the sum
of signals from all variants for a given protein captured
by the primary antibody. On the other hand, the mass
spectrometric analysis can detect all protein variants
affinity-retrieved by the capturing antibody. Presence of
signals in the mass spectra that do not correspond to * Correspondence: dnedelkov@intrinsicbio.com
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sequence is the first indication of protein variants exis-
tence. These signals can be initially assigned to specific
variants and modifications by accurate measurements of
the observed mass shifts and knowledge of the protein
sequence and possible modifications, and are further
verified using proteolytic digestion and mapping experi-
ments [4-6].
Presented here is a quantitative mass spectrometric
immunoassay for cystatin C variants. Cystatin C is a ser-
ine proteinase inhibitor belonging to the type 2 cystatin
gene family [7,8]. It is a non-glycosilated single chain
protein with a molecular weight of 13,343. Cystatin C has
been indicated in numerous pathological states [9-11],
most notably in renal failure [12,13]. A variant of human
cystatin C (L68Q) is an amyloidogenic protein deposited
in the cerebral vasculature of patients with hereditary
cerebral hemorrhage with amyloidosis [14-16]. We have
also reported on the existence of several cystatin variants
[17,18], using a qualitative cystatin C assay. In this work
we present the development, full characterization, and
validation of quantitative mass spectrometric immunoas-
say for cystatin C and its variants, and apply the assay to
determine the individual human plasma concentration of
several cystatin C variants.
Results
Internal reference standard
In the past we have utilized homologous proteins from
other animal species that are recognized by the same anti-
body that binds the human antigen, so that upon spiking
of the IRS into the analytical sample, the human protein
and its animal homologue are retrieved by the single anti-
body. The two proteins register in the same region of the
mass spectrum, but at a slightly different m/z value
[4,19,20]. However, this approach has its shortcomings in
that the concentration of the IRS can oftentimes vary in
different lots of animal sera (if purified protein is not avail-
able, as often it is the case). Furthermore, each protein
assay requires different IRS, which by itself complicates
the development of multiple assays. Hence, we took on
the novel idea that a single, unrelated protein may serve as
an IRS if an antibody toward that protein is co-immobi-
lized with the antibody toward the targeted human pro-
tein, and the analytical samples are spiked with constant
amounts of that IRS. An important prerequisite for this
type of IRS is that it should not be present in human
plasma or serum, so that its spiked concentration in the
analytical samples is always constant. Also, the IRS should
produce signals in the mass spectra that are in close proxi-
mity to the signal of the targeted protein, so that the same
MS acquisition parameters can be used for both proteins.
We selected beta-lactoglobulin as an IRS for the cystatin C
assay (and potentially other assays as well). Beta-
lactoglobulin (BL) is the major whey protein of cow’sm i l k ,
and is also present in many other mammalian species, but
not in humans. It is easily obtainable in large quantities
and is very affordable (another important factor in the
design of the assay). It has a molecular weight of 18,281,
which is relatively close to that of human cystatin C
(MW = 13,343).
Assay optimization
The first step in the assay optimization was determina-
tion of the ratios of the immobilized cysC and BL antibo-
dies in the affinity pipettes. The general idea is that there
should be more CysC antibody so that it can accurately
quantify the varying concentrations of CysC in the sam-
ples; and less BL antibody because the amount of BL
spiked in the samples can be easily controlled. After sev-
eral empirical iterations, which involved immobilizing
both CysC and BL antibodies in various mass ratios onto
the microcolumns, it was determined that the optimal
mass ratio of the two antibodies was 8.5:1 (CysC:BL).
The optimal concentration and volume of BL spiked into
the samples were determined next, by starting first with
fixed spike volumes containing increasing BL concentra-
tions (i.e., 1 mg/L, 10 mg/L BL, etc), and then using fixed
concentrations of BL but increasing the spiking volumes
(5, 10 μL, etc.). From these experiments, the optimal BL
concentration and volume were determined to be 10 mg/
La n d5μL, respectively. At this concentration, the BL
present in the analytical sample saturates the anti-BL
antibody, thus producing constant signals in the resulting
mass spectra (this is an important prerequisite for the
IRS). Next, various volumes (e.g., 5, 10, 20 μL) and dilu-
tions (undiluted, 5-times and 10-times diluted) of human
serum or plasma were utilized to determine the optimal
sample volume into the analytical samples. It is very
important not to saturate the anti-CysC antibody so that
increased concentrations of cysC can be readily quanti-
fied with the assay. It was determined that 5 μLo fs e r u m
or plasma, diluted 2-fold into assay buffer, provided the
best results. At normal concentrations of cystatin C in
plasma (~1 mg/L), these volume and concentration
translate into less than 200 fmoles of cystatin C in the
analytical samples.
Standard curve
The standard curve was optimized and determined in
parallel with the sample volume optimization. After sev-
eral iterations, a 6-point standard curve was selected,
spanning the range from 0.0312 to 1.0 mg/L cystatin C.
An example of the standard curve, along with represen-
tative mass spectra, is shown in Figure 1. The response
is linear across the entire range, with a coefficient of
determination (R
2 = 0.998) and standard error of esti-
m a t e( S E E=0 . 0 7 0 8 ) .I tw a sf o u n dt h a tt h a tt h i sr a n g e
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concentration of cystatin C in all of the examined
human plasma and serum samples. From the ratios of
the CysC/BL peak heights and using a standard curve
that was generated in parallel with the analytical sam-
ples analyses, the concentrations of cystatin C and its
variants in the samples were determined. Operationally,
we first determined the CysC/BL peak heights ratios for
each cysC form in the sample, summed them up, deter-
mined the total cystatin C concentration using the stan-
dard curve, and then determined the concentration of
the individual forms based on their percentage of the
total cystatin C concentration.
Cystatin C isoforms detection
A typical mass spectrum resulting from the cystatin C
mass spectrometric immunoassay of a human plasma
sample is shown in Figure 2. Clearly present are signals
for BL and CysC along with several cystatin C variants:
CysC containing hydroxyproline at position 3 (CysC
3Pro-OH; MW = 13,359), CysC missing its N-terminal
Serine (CysC des-S, MW = 13,260), and CysC missing
its three N-terminal residues (CysC des-SSP, MW =
13,076). These variants have been detected and identi-
fied in previous studies [17,18]. Because CysC 3Pro-OH
exhibits similar mass to that of the L68Q variant
(MW = 13,358), we performed tryptic digests and pep-
tide mapping experiments to confirm the identity of the
hydroxyl-CysC in each sample (results not shown).
Assay parameters
The intra-assay precision (within-run) was determined
by analyzing three plasma samples, in triplicates, each
with a single standard curve. The inter-assay precision
(run-to-run) was determined by analyzing one plasma
sample three times, on different days, with separate
standard curves each time. The results are shown in
Table 1, and indicate CVs of less than 10%. To deter-
mine the linearity of the assay, serum samples with
known cystatin C concentration were serially diluted,
analyzed with the mass spectrometric immunoassay to
determine the cystatin C concentrations, and the results
compared to those expected (Table 2). Spiking recovery
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Figure 1 (a) Representative cystatin C standards mass spectra,
and (b) Standard curve generated with the cystatin C (cysC)
mass spectrometric immunoassay by using beta-lactoglobulin
(BL) as an internal reference standard.
m/z
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cysC des-S
native cysC cysC 3Pro-OH
BL
Figure 2 Typical mass spectrum resulting from analysis of
cystatin C from a human plasma sample.
Table 1 Intra-and inter-assay precision
Intra-assay CVs Inter-assay CV
Sample 1 2 3 STDV 0.040
MEAN 0.380
STDV: 0.002 0.012 0.005 CV 9.84
MEAN: 0.414 0.327 0.413
CV: 0.497 3.82 1.14
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ples with different amounts of recombinant human
Cystatin C, followed by analysis with the assay to deter-
mine the total cystatin C concentration, and comparison
of the results with those expected (Table 3). In a final
test of the assay, eighteen serum samples were analyzed
both by the mass spectrometric immunoassay and a
commercially available ELISA, and the cystatin C con-
centrations determined with the two methods were
compared. The graph shown in Figure 3 indicates good
correlation between the two set of numbers (Passing &
Bablok fit of 0.09+0.69x) [21], validating the results
obtained with the new cystatin C assay.
Human plasma samples screening
The fully-developed, characterized, and validated cysta-
tin C mass spectrometric immunoassay was then used
to analyze a set of human plasma samples in a high
throughput mode. Forty-four sodium heparin plasma
samples were utilized to prepare 88 analytical samples
(each sample was prepared in duplicate, at different
dilutions) and placed in columns 2-12 of a 96-well
microplate. The standard curve samples were placed in
column 1, along with a control sample with a known
cystatin C concentration. The 96 cystatin C assays were
executed in parallel using the Multimek 96 channel
pipettor. Following mass spectrometry analysis and spec-
tra processing, a standard curve was constructed from
t h ed a t ai nc o l u m n1 ,a n dt h ep e r f o r m a n c eo ft h ea s s a y
verified with the control sample. The concentrations of
cystatin C and its variants were then individually deter-
mined, averaged (from the two analyses for each sample)
and are presented in Table 4. The average of the total
concentration of cystatin C in the samples is 0.94 mg/L,
and correlates well with that previously established
(~0.85 mg/L) using ELISA approaches [22]. The major
fraction of cystatin C is cysC 3Pro-OH, followed by the
native form. The native CysC to CysC 3Pro-OH ratio is
~1:1.25, which agrees with previously reported values
for the two [23,24]. The two truncated forms (des-S and
des-SSP) are present in all samples, albeit at much
lower concentration (each is less than <10% of the total
CysC). One sample (#44) also contains point mutations
that results in a -30Da peak shift (mass spectra not
shown). This mutation was detected in our previous
study [18], and again, it was observed only in a sample
obtained from a male subject. In all, the assay per-
formed well and was executed in a high-throughput
manner: the 96 samples incubation and deposition onto
the MALDI target was executed in 30 min, while the
mass spectra acquisition/data processing was performed
in 3 hours.
Conclusions
The assay presented in this works utilizes mass spectro-
metry to fully quantify cystatin C variants. Similar MS
assays can also be designed for other proteins to enable
full quantification of their post-translationally modified
forms. There are other affinity-based MS methods for
protein quantification. Among the earliest is SELDI,
which utilizes MALDI target-bound antibodies for pro-
tein retrieval [25]. In a similar approach called iMALDI,
affinity beads with immobilized anti-peptide antibodies
Table 2 Assay linearity
Sample Dilution Observed Expected Recovery
mg/L mg/L O/E %
1 0.709
2x 0.316 0.355 89.0
4x 0.168 0.177 94.9
8x 0.093 0.089 104
2 0.514
2x 0.273 0.257 106
4x 0.122 0.129 94.6
8x 0.071 0.064 110
Table 3 Spiking recovery
Sample Observed Expected Recovery
mg/L mg/L O/E%
1 0.326
0.704 0.826 85.2
1.41 1.33 106
1.72 1.83 94.2
2 0.530
0.736 0.780 94.4
1.02 1.03 99.0
1.41 1.53 92.2
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Figure 3 Cystatin C mass spectrometric immunoassay and
standard ELISA method comparison.
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isotopically labeled standards, which are then MS-ana-
lyzed when the affinity beads are placed on a MALDI
target [26]. Most popular today are approaches based on
single/multiple reaction monitoring (SRM/MRM) LC-
MS/MS. Even though they can be executed without affi-
nity enrichment (for quantification of medium-to-high
level plasma proteins) [27], the immunoaffinity separa-
tion is the key enabling step for quantification of low-
level plasma proteins. SISCAPA is the most advanced
MRM LC-MS/MS approach [28,29]. SISCAPA utilizes
isotopically labeled peptides as internal reference stan-
dards for surrogate protein quantification via enzymati-
cally-generated peptides which are retrieved by a single
antibody. While SRM/MRM LC-MS may be suitable for
quantification of low abundance proteins for which ELI-
SAs are not available, they typically quantify the proteins
via few surrogate peptide fragments. Hence, a large por-
tion of the protein sequence is excluded from the inter-
rogation, leaving out important information about
possible variants with potential clinical implications.
Furthermore, their complex, multi-step protein identifi-
cation process introduces an array of possible paths that
can lead to reproducibility issues [30-32]. Finally, the
SRM/MRM LC-MS assays are designed a-priori for
detection of specific peptides, which eliminates the abil-
ity to detect novel truncations and mutations. On the
other hand, the assay and methodology presented here
utilize a simplistic two-step approach to native and
intact protein analysis - in many ways similar to that in
well established enzymatic immunoassays. However, it is
the last step of the assay - the mass spectrometric detec-
tion - that enables differentiation of the multiple protein
variants. Enzymatic immunoassay are oblivious to pro-
tein modifications, unless an antibody is designed that
specifically recognizes a single protein variant (a Hercu-
lean task by itself). The mass spectrometric immunoas-
says, on the other hand, are designed with detection of
protein modifications in mind. With the added quantita-
tive feature, these assays are poised to change the way
we look at protein modifications and their role in
diseases - one protein at a time.
Methods
Reagents
Rabbit anti-human polyclonal antibody to cystatin C
(cysC) was obtained from DAKO (Carpinteria, CA, USA,
Catalog No. A0451, 17 g/L). Rabbit anti-human polyclo-
nal antibody to beta-lactoglobulin (BL) was obtained
from GeneTex (Irvine, CA, Cat. No. GTX77272, 1 mg/
mL). Recombinant human cystatin C was purchased
f r o mH y T e s t( T u r k u ,F i n l a n d ,C a t .N o .8 C Y 5 ) .B e t a - l a c -
toglobulin from bovine milk (Cat. No. L8005), 1,1’ Carbo-
nyldiimidazole (115533), TWEEN 20 (P7949), TRIS
(T-6128), Dithiothreitol (DTT, 43815) and a-cyano -4-
hydroxycinnamic acid (476870) were obtained from
Sigma-Aldrich (St. Lous, MO). Affinity pipettes fitted
with porous microcolumns were obtained from Intrinsic
B i o p r o b e s( T e m p e ,A Z ,C a tN o .I B I - C M D - R 9 6 ) .
Table 4 Cystatin C variants concentrations
Sample native
cysC
cysC
3Pro-OH
cysC
des-S
cysC
des-SSP
Total
cysC
[mg/L] [mg/L] [mg/L] [mg/L] [mg/L]
1 0.25 0.33 0.07 0.07 0.71
2 0.32 0.41 0.08 0.03 0.84
3 0.39 0.48 0.09 0.08 1.04
4 0.42 0.54 0.08 0.08 1.11
5 0.35 0.46 0.11 0.11 1.02
6 0.27 0.35 0.07 0.09 0.79
7 0.24 0.34 0.06 0.04 0.68
8 0.69 0.83 0.15 0.18 1.85
9 0.45 0.58 0.12 0.11 1.27
10 0.29 0.38 0.08 0.09 0.85
11 0.40 0.55 0.13 0.14 1.22
12 0.40 0.46 0.09 0.09 1.04
13 0.30 0.38 0.07 0.08 0.83
14 0.22 0.30 0.07 0.08 0.67
15 0.36 0.45 0.09 0.10 1.00
16 0.20 0.26 0.09 0.04 0.58
17 0.23 0.31 0.05 0.05 0.64
18 0.38 0.47 0.09 0.09 1.03
19 0.40 0.52 0.09 0.09 1.09
20 0.41 0.53 0.09 0.08 1.11
21 0.38 0.47 0.10 0.07 1.02
22 0.31 0.41 0.08 0.06 0.85
23 0.36 0.50 0.08 0.06 1.00
24 0.34 0.45 0.08 0.09 0.96
25 0.13 0.18 0.04 0.03 0.38
26 0.34 0.43 0.11 0.10 0.98
27 0.28 0.34 0.08 0.07 0.77
28 0.32 0.41 0.09 0.09 0.91
29 0.20 0.25 0.05 0.05 0.54
30 0.33 0.40 0.08 0.07 0.87
31 0.41 0.49 0.08 0.08 1.06
32 0.39 0.52 0.10 0.07 1.09
33 0.32 0.40 0.07 0.07 0.86
34 0.23 0.29 0.09 0.09 0.70
35 0.18 0.22 0.05 0.05 0.50
36 0.48 0.69 0.15 0.12 1.44
37 0.46 0.62 0.12 0.11 1.31
38 0.42 0.56 0.12 0.09 1.18
39 0.23 0.30 0.08 0.09 0.70
40 0.39 0.51 0.09 0.07 1.06
41 0.36 0.43 0.05 0.11 0.95
42 0.24 0.33 0.05 0.04 0.67
43 0.47 0.57 0.11 0.10 1.25
44 0.45 0.49 0.06 0.11 1.12
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Page 5 of 8Phosphate buffered saline was obtained from Thermo
Scientific (Rockford, IL, Cat. No. 28374). Sterile
water (Cat. No. AB02120), acetone (AB00636), MES
(AB01235), acetonitrile (AB00120) and trifluoracetic acid
(AB02010) were purchased from American Bionalytical
(Natick, MA). Methyl-1 pyrrolidone-2 was obtained from
E M DC h e m i c a l s( G i b b s t o w n ,N J ,C a t .N o .M X 1 9 3 2 - 5 ) .
N-octylglucoside was obtained from Roche Applied
Science (Indianapolis, IN, Cat. No. 10634425001). Cysta-
t i nE L I S Ak i tw a so b t a i n e df r o mB i o v e n d o r( C a n d l e r ,
NC, Cat. No. RD191009100). Sequencing grade modified
trypsin was obtained from Promega (Madison, WI, Cat.
No. V511).
Instrumentation
Derivatization of the affinity pipettes with antibodies
and high-throughput mass spectrometric immunoassays
were performed on a Multimek 96 automated 96-chan-
nel pipettor (Beckman Coulter, Brea, CA). Manual mass
spectrometric immunoassays were performed with the
help of an 8-channel Finnpipette Novus multichannel
pipetter (Thermo Fisher Scientific, Waltham, MA). Mass
spectrometry was performed on an Autoflex II MALDI-
TOF (linear spectra) and Autoflex II TOF/TOF MALDI-
TOF (reflectron spectra) mass spectrometers (Bruker,
Billerica, MA). ELISA readouts were obtained on Cary
50 spectrophotometer equiped with a microplate reader
accesory (Varian Instruments, Walnut Creek, CA).
The cystatin C ELISA was carried out according to the
kit manufacturer instructions (Biovendor, Cat. No.
RD191009100)
Human serum and plasma samples
Forty-four Na-heparin human plasma samples and eigh-
teen human serum samples were obtained from Pro-
MedDX (Norton, MA, USA). The samples were collected
at certified blood donor and medical centers and desig-
nated as normal based on their non-reactivity for common
blood infectious agents and the donor information itself.
The samples were labeled only with a barcode and sup-
plied with an accompanying specification sheet containing
information only about the gender and age, ensuring
proper privacy protection.
Preparation of affinity pipettes
Ninety-six affinity pipettes were mounted on the head of
the Multimek 96 pipettor and initially rinsed with
200 mM HCl (20 cycles, each cycle consisting of an
aspiration and dispense of a 150 μLv o l u m e ) ,f o l l o w e d
by a water rinse (5 cycles) and acetone rinse (5 cycles).
To activate the surface of the microcolumns contained
within, the pipettes were immersed into a tray contain-
ing 100 mg/mL 1,1’ Carbonyldiimidazole (in methyl-1
pyrrolidone-2), and 500 cycles of 100 μL aspirations and
dispenses through each affinity pipette were performed.
Two rinses with methyl-1 pyrrolidone-2 (10 cycles each,
150 μL volumes) and a final rinse with acetone (10
cycles, 150 μL) followed. The affinity pipettes were then
immediately immersed into a microwell plate containing
the antibodies solutions (0.085 mg/mL cystatin C anti-
body, and 0.01 mg/mL beta-lactoglobulin antibody, in
10 mM MES) and 800 cycles of aspirations and dis-
penses of 50 μL volumes were performed to bind
the antibodies to the activated microcolumns surfaces.
Two rinses with 60 mM HCl followed (30 cycles each,
100 μL), ending with two final rinses with assay buffer
(PBS w/0.1% TWEEN, 30 cycles each, 100 μL). The anti-
body-derivatized pipettes were stored at 4°C until used.
Preparation of standards and analytical samples
For the generation of the standard curve, a solution con-
taining 1.0 mg/L recombinant cystatin C was prepared
(Standard #1) and serially diluted with assay buffer to
0.5 mg/L (Standard #2), 0.25 mg/L (Standard #3),
0.125 mg/L (Standard #4), 0.0625 mg/L (Standard #5),
and 0.0312 mg/L (Standard #6). Five microliters of
each of these standards were added to microtubes con-
taining 140 μL assay buffer and 5 μLo f1 0m g / Lb e t a -
lactoglobulin. For the analytical samples, the standard
solutions were substituted with human plasma or serum
sample (diluted 2-fold into assay buffer).
Mass spectrometric immunoassay
The antibody-derivatized affinity pipettes were mounted
onto the head of the Multimek pipettor and initially
rinsed with assay buffer (10 aspirations and dispense
cycles, 100 μL volumes each). Next, the pipettes were
immersed into a microplate containing the samples and
100 aspirations and dispense cycles were performed
(100 μL volumes each) allowing for affinity capture of
cystatin C and beta lactoglobulin. The pipettes were
then rinsed with assay buffer (100 cycles), and twice
with water (10 cycles each). In preparation of elution,
the affinity pipettes containing the retrieved protein
were rinsed with 1 mM N-octylglucoside (single cycle
with a 150 μL aliquot) in order to homogenize the sub-
sequent MALDI matrix draw and elution, by completely
wetting the porous microcolumns inside the pipettes.
For elution of the captured proteins, 6 μL aliquots of
MALDI matrix (25 g/L a-cyano-4-hydroxycinnamic acid
in aqueous solution containing 33% (v/v) acetonitrile,
and 0.4% (v/v) trifluoroacetic acid) were aspired into the
affinity pipettes, and after a 10 second delay (to allow
for the dissociation of the protein from the capturing
antibody), the eluates from all 96 affinity pipettes con-
taining the targeted proteins were dispensed directly
onto a 96-well formatted MALDI target. Following air-
drying and visual inspection of the sample spots, linear
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mode using a 1.7 kV draw out pulse, 200 ns delay, and
a full accelerating potential of 20 kV. Five mass spectra
were acquired from each sample spot, each spectrum
consisting of three-hundred laser shots. The mass spectra
were internally calibrated with the singly and doubly
charged beta-lactoglobulin signals, and further processed
(baseline subtracted and smoothed) with Flex Analysis
software (Bruker Daltonics). The peak heights for the
cystatin C and beta-lactoglobulin signals were measured
and entered into an Excel spreadsheet. The ratios of the
cysC/BL peak heights were calculated, and the average
ratio for each sample determined. A standard curve was
generated by plotting the CysC/BL ratios against the con-
centration of the human cystatin C standards, and the
data was fitted with a linear trendline using Sigma Plot
(Systat Software, San Jose, CA). This standard curve was
then utilized to determine the absolute concentration of
cystatin C and its variants in the analytical samples.
Tryptic peptide mapping
Tryptic digestion was performed directly on the cystatin
C eluates deposited onto the MALDI target after the
mass spectrometric immunoassay of the human serum
samples [6]. A 10 μLa l i q u o to f2 5m MT R I S ,p H9 . 1 ,
containing 0.5 mg/L trypsin (w/or w/o 1 mM DTT) was
added onto each analytical sample spot and the entire
MALDI plate was placed into a humidified enclave, at
40°C. To keep the samples solvated, one 10 μL aliquot
of water was added to each spot at ~10 min into the
digestion. Digestion was terminated after 20 min by air-
drying the plate. The sample spots were re-hydrated
with 5 μLa l i q u o t so f0 . 8 %T F A ,a n da l l o w e dt od r y
again. Following matrix re-crystallization, reflectron
mass spectra were acquired with a delayed extraction
mode using a 2.1 kV draw out pulse, 1100 ns delay, an
ion mirror voltage of 20 kV, and a full accelerating
potential of 19 kV
Abbreviations
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